Ziv Savin1, Izabella Lejbkowicz2, Lea Glass-Marmor3, Idit Lavi4, Sara Rosenblum5, Ariel Miller6. 1. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron Street, Haifa, Israel. Electronic address: zivsavin23@gmail.com. 2. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron Street, Haifa, Israel; Multiple Sclerosis & Brain Research Center, Carmel Medical Center, 7 Michal Street, Haifa, Israel. Electronic address: izabella@tx.technion.ac.il. 3. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron Street, Haifa, Israel; Multiple Sclerosis & Brain Research Center, Carmel Medical Center, 7 Michal Street, Haifa, Israel. Electronic address: leam@tx.technion.ac.il. 4. Department of Community Medicine and Epidemiology, Carmel Medical Center, 7 Michal Street, Haifa, Israel. Electronic address: lavi_idit@clalit.org.il. 5. The Laboratory of Complex Human Activity and Participation (CHAP), Department of Occupational Therapy, Faculty of Social Welfare & Health Sciences, University of Haifa, 199 Aba Khoushy Avenue, Haifa, Israel. Electronic address: rosens@univ.haifa.ac.il. 6. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Efron Street, Haifa, Israel; Multiple Sclerosis & Brain Research Center, Carmel Medical Center, 7 Michal Street, Haifa, Israel. Electronic address: milleras@netvision.net.il.
Abstract
BACKGROUND: Persons with MS (PwMS) commonly present ambulatory and manual dysfunctions. While ambulation is recognized as important to PwMS, manual dysfunction is only lately gaining attention. Fampridine-PR was approved for MS ambulatory impairments. Anecdotal evidences indicate possible therapeutic effects on manual function. OBJECTIVE: To comprehensively assess the effect of Fampridine-PR on manual functions of PwMS. METHODS: Twenty six PwMS with ambulatory and manual dysfunction assessed before, 1 and 3months after treatment with Fampridine-PR, applying Timed 25-Foot Walk (T25FW) for ambulation while manual functions were evaluated by several tools addressing the International Classification of Functioning (ICF) concepts. This includes hand grip and pinch strength, 9 Hole Peg Test (9HPT), Arthritis Hand Function Test (AHFT), activities of daily life (ADL) tests, ABILHAND questionnaire and Computerized Penmanship Evaluation Tool (ComPET). RESULTS: Fampridine-PR increased dominant hand grip and pinch strength 1month following treatment initiation by 12% and 10% (p<0.05), respectively. 9HPT improved by 11.3% after 3months of treatment (p<0.05%) and ABILHAND improved by 16% and 31% (p<0.05%) after 1 and 3months of treatment. Mean stroke duration in air of the name writing task improved by 21% (p<0.05) following 3months of treatment. T25FW results were similar to previous reports. CONCLUSION: The results of this pilot study suggest that Fampridine-PR improves manual function of PwMS. Methods herein indicate that an integrative approach may be useful for evaluation of manual function in MS and in additional neurological diseases.
BACKGROUND:Persons with MS (PwMS) commonly present ambulatory and manual dysfunctions. While ambulation is recognized as important to PwMS, manual dysfunction is only lately gaining attention. Fampridine-PR was approved for MS ambulatory impairments. Anecdotal evidences indicate possible therapeutic effects on manual function. OBJECTIVE: To comprehensively assess the effect of Fampridine-PR on manual functions of PwMS. METHODS: Twenty six PwMS with ambulatory and manual dysfunction assessed before, 1 and 3months after treatment with Fampridine-PR, applying Timed 25-Foot Walk (T25FW) for ambulation while manual functions were evaluated by several tools addressing the International Classification of Functioning (ICF) concepts. This includes hand grip and pinch strength, 9 Hole Peg Test (9HPT), Arthritis Hand Function Test (AHFT), activities of daily life (ADL) tests, ABILHAND questionnaire and Computerized Penmanship Evaluation Tool (ComPET). RESULTS:Fampridine-PR increased dominant hand grip and pinch strength 1month following treatment initiation by 12% and 10% (p<0.05), respectively. 9HPT improved by 11.3% after 3months of treatment (p<0.05%) and ABILHAND improved by 16% and 31% (p<0.05%) after 1 and 3months of treatment. Mean stroke duration in air of the name writing task improved by 21% (p<0.05) following 3months of treatment. T25FW results were similar to previous reports. CONCLUSION: The results of this pilot study suggest that Fampridine-PR improves manual function of PwMS. Methods herein indicate that an integrative approach may be useful for evaluation of manual function in MS and in additional neurological diseases.
Authors: Scott D Newsome; Gloria von Geldern; Haochang Shou; Moira Baynes; Rhul E R Marasigan; Peter A Calabresi; Kathleen M Zackowski Journal: Mult Scler Relat Disord Date: 2019-05-06 Impact factor: 4.339
Authors: Ka-Hoo Lam; Caspar E P van Munster; Marcus D'Souza; Saskia Steinheimer; Christian P Kamm; Jessica Burggraaff; Matthew Johnson; Yordan Zaykov; Jonas Dorn; Frank Dahlke; Ludwig Kappos; Joep Killestein; Bernard Uitdehaag Journal: Int J MS Care Date: 2022-06-20
Authors: Peter Feys; Ilse Lamers; Gordon Francis; Ralph Benedict; Glenn Phillips; Nicholas LaRocca; Lynn D Hudson; Richard Rudick Journal: Mult Scler Date: 2017-02-16 Impact factor: 6.312
Authors: Caspar Ep van Munster; Levent Kaya; Morgan Obura; Nynke F Kalkers; Bernard Mj Uitdehaag Journal: Mult Scler Date: 2019-01-18 Impact factor: 6.312
Authors: Philipp Albrecht; Ingrid Kristine Bjørnå; David Brassat; Rachel Farrell; Peter Feys; Jeremy Hobart; Raymond Hupperts; Michael Linnebank; Jožef Magdič; Celia Oreja-Guevara; Carlo Pozzilli; Antonio Vasco Salgado; Tjalf Ziemssen Journal: Ther Adv Neurol Disord Date: 2018-10-05 Impact factor: 6.570